Pharmaceutical research in paediatric populations and the new EU Paediatric Legislation: an industry perspective

Area of Science:

• Regulatory Science
• Pediatric Pharmacology
• Drug Development

Background:

• Many medicines used in children are prescribed off-label, leading to ethical concerns and limited access to innovative treatments.
• Historically, children have been excluded from drug development, necessitating a global consensus on obtaining pediatric data.
• The European Union (EU) and the United States (US) recognized the need for legal obligations for pharmaceutical companies to conduct pediatric studies.

Purpose of the Study:

• To present the new European Paediatric Regulation implemented in 2007.
• To illustrate the rationale behind the regulation using pediatric psychopharmacology as a case study.
• To discuss the implications of the regulation on pediatric research from an industry viewpoint.

Main Methods:

• Review of the European Paediatric Regulation (entered into force in 2007).
• Analysis of pediatric psychopharmacology to demonstrate the regulation's rationale.
• Discussion of industry perspectives on the consequences of the regulation for pediatric research.

Main Results:

• The European Paediatric Regulation establishes a new framework for evaluating the efficacy and safety of medicines for children.
• Paediatric drug development remains challenging due to numerous hurdles in conducting research within this population.
• The regulation presents an opportunity to improve children's health through advancements in pediatric medicine research.

Conclusions:

• The European Paediatric Regulation marks a significant advancement in European drug regulatory history for pediatric populations.
• Further international collaboration is recommended to facilitate global paediatric drug development plans.
• Addressing challenges in pediatric research is crucial for optimizing the benefits of the new regulatory framework.